Laurent Audoly

Laurent is co-founder, CEO & Chairman of Parthenon Therapeutics. He has contributed to the identification and development of seven novel medicines (Xeljanz®, Hemangiol®, Javlor®, Renflexis®, Brenzys®, Ontruzant®, Hadlima® – biologics and small molecules) addressing unmet medical need across multiple disease areas that generate > $3B in annual sales.

Laurent has also led business and R&D functions in both pharma and biotech (US and EU), including CEO of Kymera Therapeutics, head of R&D with Pierre Fabre Pharmaceuticals, and positions of increasing leadership responsibilities on the business and science fronts at Pfizer, Merck, and Pieris contributing to the advancement of 21 drug candidates into clinical development across multiple disease areas and modalities. He has completed partnering transactions worth over $3B in biobucks and raised > $250M.

He studied chemistry and pharmacology (Ph.D.) at Vanderbilt University and completed postdoctoral training at UNC/Chapel Hill and Duke University where he was the recipient of an American Heart Association Fellowship. He has co-authored over 70 papers and patents. Laurent also serves as an independent director on the board of Cytovia, Ixaka, Ermium, and is a member of Ventus' scientific advisory board.